Virometix: Virometix to kick off in-human studies of its vaccine against virus infection

The Belgian health authority, FAMHP, has approved Virometrix's clinical trial application for the first-in-human phase 1 study of its respiratory syncytial virus (RSV) vaccine candidate, V-306. The startup secured funds to initiate the project.